-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.Börse Hong Kong Stock Exchange-
BeigeneBörse Börse StuttgartSymbol 49BA
-
BeiGene Ltd Ordinary SharesBörse Börse FrankfurtISIN KYG1146Y1017 WKN: A144ENSymbol 49B
-
BEIGENE LTD-ADRBörse Tradegate System der Deutsche Börse AG (60%)Symbol 49BA
-
BEIGENE LTD-ADRBörse Gettex System der Börse MünchenSymbol 49BA
-
BEIGENE LTD-ADRBörse Börse DüsseldorfSymbol 49BA
-
BEIGENE LTD-ADRBörse Börse MünchenSymbol 49BA
-
BEIGENE LTD-ADRBörse Quotrix System der Börse DüsseldorfSymbol 49BA
-
BEIGENE LTD-ADRBörse Börse BerlinSymbol 49BA
-
BEIGENE LTD-ADRBörse Börse FrankfurtSymbol 49BA
-
BeigeneBörse NasdaqISIN US07725L1026 WKN: A1437NSymbol BGNE
-
BeiGene, Ltd.Börse Bolsa Mexicana de Valore Mexiko-StadtISIN US07725L1026
-
ISIN US07725L1026 WKN: A1437NSymbol BGNE
-
BeigeneBörse Hong Kong Stock Exchange
-
HKD
-
BeiGene, Ltd.Börse BVMF
-
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
31.242.956.800 oder 27.236.000.000
Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:
4.600 oder 4.200 oder 9.400 Mitarbeiter
Beigene outperformed den DAX um +62 % vom 08.08.2018 bis 16.07.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 299,2 USD -2,94%
Portrait der Beigene Aktie
Das Unternehmen BeiGene, Ltd aus Kaiman Inseln beschäftigt 6.067 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie & Pharmazeutika, Biotechnologie tätig.
Die Beigene Aktie konnte seit dem 08.08.2018 eine Rendite von 87% erwirtschaften.
Das Unternehmen BeiGene, Ltd ist in ungefähr 16 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter VanEck Vectors Biotech ETF gewichtet Beigene mit 4,11% im ETF.
Entdecke die 6 ETFs in denen BeiGene, Ltd am höchsten gewichtet ist Insgesamt in 16 ETFs enthalten
Dir gefallen die Informationen zu Beigene?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Dir gefallen die Informationen zu Beigene?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Dir gefallen die Informationen zu Beigene?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Dir gefallen die Informationen zu Beigene?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
54 News & Informationen zur Beigene Aktie
2 Dow Stocks to Buy Hand Over Fist This Month
The Dow Jones Industrial Average (DJIA) notched a fresh record close yesterday, despite fears surrounding the resurgence of COVID-19 cases and geopoli…
Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation
/PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported…
4 Top Healthcare Stocks on the Dow Jones Index
The Dow Jones Industrial Average closed at a record high last week, with stocks tied to economic recovery gaining significantly after a strong jobs re…
Were Hedge Funds Right About TransDigm Group Incorporated (TDG)?
A whopping number of 13F filings filed with U.S.
Amgen : Announces 2021 Third Quarter Dividend
THOUSAND OAKS, Calif., July 30, 2021 /PRNewswire/ — Amgen today announced that its Board of Directors declared a $1.76 per share dividend for the third quarter of 2021. The dividend will… | July 30, 2021
BeiGene Announces Approval In Canada Of BRUKINSA® (Zanubrutinib) For The Treatment Of Patients With Mantle Cell Lymphoma
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve
Leap Therapeutics To Present At The ESMO 2021 Virtual Congress
CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and
BioNTech : Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S (Form 6-K)
Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
… | July 23, 2021
BeiGene, Ltd. (BGNE) Fell Out Of Favor With Hedge Funds
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms…
Global Bispecific Antibody Market Report 2021-2024 With Focus On China
DUBLIN, July 13, 2021 /PRNewswire/ — The “Global and China Bispecific Antibody Market Insight Report, 2021-2024” report has been added to
Hedge Funds Are Souring On PACCAR Inc (PCAR)
In this article we will check out the progression of hedge fund sentiment towards PACCAR Inc (NASDAQ:PCAR) and determine whether it is a good investment…
BeiGene : Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
BeiGene, Ltd. , a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration has… | July 9, 2021
Tezepelumab Granted Priority Review By U.S. FDA
/PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and…
BeiGene Announces Acceptance Of A Supplemental Biologics License Application In China For Tislelizumab In Esophageal Squamous Cell Carcinoma (ESCC)
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today
Beigene Receives Approval for $3 Billion Shanghai STAR Listing By Investing.com
Beigene Receives Approval for $3 Billion Shanghai STAR Listing
BeiGene : Financial Information (Form 8-K)
Financial Information
BeiGene, Ltd. previously submitted a listing application for a proposed public offering of the Company's ordinary shares and initial… | June 30, 2021
Ultragenyx Pharmaceutical : Management Change/Compensation (Form 8-K)
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 29, 2021, the Board of… | June 30, 2021
Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development…
Primecap Odyssey Funds' 2021 Semiannual Letter to Shareholders
GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Discussion of markets and holdings
Hedge Funds Have Never Been This Bullish On Brown-Forman Corporation (BF)
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900…
EV Maker Xpeng Said to Get Nod for $2 Billion Hong Kong Listing
(Bloomberg) — New York-traded electric-vehicle maker Xpeng Inc. has received the green light from the Hong Kong stock exchange to list in the city, according to people with knowledge of the matter, the latest homecoming share sale by a Chinese company.
Hedge Funds Are Selling D.R. Horton, Inc. (DHI)
In this article we will analyze whether D.R. Horton, Inc. (NYSE:DHI) is a good investment right now by following the lead of some of the best investors…
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
Pre-open movers
U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session.
The …
5 Stocks To Watch For June 21, 2021
Some of the stocks that may grab investor focus today are: Amazon.com, Inc. (NASDAQ: AMZN) will remain in focus with the company’s two-day Prime …
BeiGene : Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
The combination showed preliminary antitumor activity in patients with unresectable or metastatic melanoma refractory or resistant to PD-1/L1 inhibitors and platinum-resistant ovarian cancer in an… | April 11, 2021
BeiGene Presents Clinical Data On Sitravatinib In Combination With Tislelizumab At The AACR Annual Meeting 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide,
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 14) 10X …
BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China
BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET Thursday, 503 stocks hit new 52-week highs.
Noteworthy Points: Taiwan Semiconductor (NYSE:TSM) was the largest firm on a …
Beigene Stock Breaks Out To Record High On Cancer Drug OK In China
Beigene stock broke out and surged to a record high Thursday after China's regulators approved its lung cancer treatment.
Beigene Surges Closer To Breakout On $2.2 Billion Deal With Novartis
Beigene stock rose Tuesday on a cancer deal with Novartis worth up to $2.2 billion, as Vir Biotechnology announced a hepatitis B deal with Gilead Sciences.
Why BeiGene, T2 Biosystems And Amneal Are Are Moving Today
BeiGene (NASDAQ:BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed …
Why BeiGene, T2 Biosystems And Amneal Are Are Moving Today
BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and …
US Divestiture Of Executive Order Banned Stocks To Benefit Mainland Investors, Asset Managers
The Hang Seng Index gained +1.32% while the Chinese companies listed in Hong Kong and within the MSCI China All Shares Index gained +0.77% as value stocks outperformed growth stocks.
Twitter, Tesla, Realty Income, Cantel Medical: What to Watch When the Stock Market Opens Today
S&P 500 futures are edging higher, pointing to muted gains after dropping on Monday.
BGNE Teams Up With NVS, Editas Slumps Over 15%, LLY's Drug Shines In TRAILBLAZER-ALZ, MESO On Watch
Today's Daily Dose brings you news about Lilly's Alzheimer's disease trial data, BeiGene's collaboration agreement with Novartis, Mesoblast's encouraging results from phase III trial of Rexlemestrocel-L in patients with chronic heart failure, and the resignation of Editas' Chief Scientific Officer.
BeiGene Collaborates With Novartis To Develop Cancer Drug; To Receive Up To $1.55 Bln Payments
(RTTNews) – China-based biotechnology companyBeiGene Ltd. (BGNE) said that it will collaborate with Novartis to develop, manufacture and commercia…
BeiGene to Collaborate With Novartis on Tislelizumab, Will Get $650 Million Upfront Payment
By Josh Beckerman
BeiGene Ltd. will collaborate with Novartis AG on development of BeiGene's anti-PD-1 antibody tislelizumab and will receive a $650 million upfront cash payment.
… | January 11, 2021
Amgen : To Achieve Carbon Neutrality By 2027
THOUSAND OAKS, Calif., Jan. 11, 2021 /PRNewswire/ — Amgen? today announced the launch of a new seven-year environmental sustainability plan, which includes a commitment to achieve carbon… | January 11, 2021
Amgen To Achieve Carbon Neutrality By 2027
/PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of a new seven-year environmental sustainability plan, which includes a commitment to achieve…